Literature DB >> 21789131

The way forward in treating pancreatic cancer.

Valeriy Sedov1, Elizabeth Poplin.   

Abstract

Entities:  

Year:  2010        PMID： 21789131      PMCID： PMC3126015          DOI： 10.1177/1758834010366254

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  21 in total

Review 1.  Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.

Authors:  Donald A Richards
Journal:  Semin Oncol       Date:  2005-08       Impact factor: 4.929

Review 2.  p16(MTS-1/CDKN2/INK4a) in cancer progression.

Authors:  J W Rocco; D Sidransky
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 3.  Precursors to invasive pancreatic cancer.

Authors:  Anirban Maitra; Noriyoshi Fukushima; Kyoichi Takaori; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2005-03       Impact factor: 3.875

4.  The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

Authors:  Jennifer Spratlin; Randeep Sangha; Darryl Glubrecht; Laith Dabbagh; James D Young; Charles Dumontet; Carol Cass; Raymond Lai; John R Mackey
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

5.  Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Authors:  E S Casper; M R Green; D P Kelsen; R T Heelan; T D Brown; C D Flombaum; B Trochanowski; P G Tarassoff
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 6.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

7.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Authors:  Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

8.  Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.

Authors:  Takao Itoi; Atsushi Sofuni; Noriyoshi Fukushima; Fumihide Itokawa; Takayoshi Tsuchiya; Toshio Kurihara; Fuminori Moriyasu; Akihiko Tsuchida; Kazuhiko Kasuya
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

9.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

Authors:  J R Mackey; R S Mani; M Selner; D Mowles; J D Young; J A Belt; C R Crawford; C E Cass
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

10.  A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.

Authors:  M J Mackenzie; D Saltman; H Hirte; J Low; C Johnson; G Pond; M J Moore
Journal:  Invest New Drugs       Date:  2007-06-22       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.